| Literature DB >> 28097740 |
Florian Kloss1,2, Viktor Krchnak3,4, Anna Krchnakova3, Sebastian Schieferdecker1,5,2, Julia Dreisbach6,7, Volker Krone7, Ute Möllmann1, Michael Hoelscher6,7, Marvin J Miller3.
Abstract
Nitrobenzothiazinones are among the most potent antituberculosis agents. Herein, we disclose an unprecedented in vivo reduction process that affords Meisenheimer complexes of the clinical candidates BTZ043 and PBTZ169. The reduction is reversible, occurs in all mammalian species investigated, has a profound influence on the in vivo ADME characteristics, and has considerable implications for the design and implementation of clinical studies. The reduction was confirmed by chemical studies that enabled the complete characterization of the Meisenheimer complex and its subsequent chemistry. Combination of the in vivo and chemical studies with LC-MS characterization and assay development also provides a basis for rational lead optimization of this very promising class of antituberculosis agents.Entities:
Keywords: DprE1 inhibitors; benzothiazinones; metabolite identification; prodrugs; transient metabolites
Mesh:
Substances:
Year: 2017 PMID: 28097740 DOI: 10.1002/anie.201609737
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336